A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.
Cutaneous rash is a common adverse event among patients with non-small cell lung cancer who receive erlotinib and may indicate that the patient will experience a significantly greater survival benefit.
Fresh strategies for grappling with the chronic, and at times critical, shortages of cancer drugs that have frustrated the
oncology community for the past decade are likely to help alleviate supply problems.
There has been stunning progress as preclinical findings of the ALK gene in patients with lung cancer were rapidly translated into the availability of an FDA-approved therapeutic ALK inhibitor, crizotinib.
The ability of cabozantinib to inhibit the RET pathway contributed to the pivotal clinical trial findings demonstrating that the novel oral agent significantly improved PFS in patients with advanced MTC.